Zoetis to Acquire Neogen’s Animal Genomics Business for $160 Million

QIAGEN Acquires Genoox

May 12, 2025

Biotechnology

QIAGEN has signed a definitive agreement to acquire Genoox, the developer of the AI-powered Franklin clinical genomics platform, for $70 million in cash plus up to $10 million in milestone payments. The acquisition adds Genoox's cloud-based AI interpretation capabilities to QIAGEN Digital Insights, expanding QIAGEN's clinical genomics and diagnostic software offerings for labs and healthcare organizations worldwide.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

Zoetis Acquires Basepaws to Expand Precision Petcare Genetics and Diagnostics

June 7, 2022

Healthcare Services

Zoetis agreed to acquire Basepaws, a privately held petcare genetics company that provides genetic tests, analytics, and early health risk assessments for pets. Zoetis said the deal will strengthen its precision animal health portfolio and inform its future petcare R&D pipeline using Basepaws’ feline genomic and microbiome database.

AstraZeneca Acquires Neogene Therapeutics

November 29, 2022

Biotechnology

AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell receptor (TCR) therapies, for up to $320 million. The acquisition strengthens AstraZeneca's oncology cell therapy capabilities by adding Neogene's discovery, development and manufacturing expertise for TCR-Ts targeting solid tumours.

Swiss Rockets AG To Acquire Complete Genomics

February 23, 2026

Healthcare Services

Complete Genomics, a U.S.-based genomic sequencing technology company, entered into a definitive agreement to be acquired by Switzerland-based life sciences group Swiss Rockets AG. The transaction is intended to scale Complete Genomics’ innovation pipeline and diversify its manufacturing capacity, with Swiss Rockets taking 100% ownership and sole control upon closing.